- Home
- PGEN vs RXRX Comparison
PGEN vs RXRX Comparison
Compare PGEN & RXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGEN | RXRX |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PGEN | RXRX |
|---|---|---|
| Price | $5.42 | $3.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $8.33 | $7.50 |
| AVG Volume (30 Days) | 4.0M | ★ 22.8M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $230,981,000.00 | $74,681,000.00 |
| Revenue This Year | $1,115.92 | $12.11 |
| Revenue Next Year | $81.04 | $82.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 26.92 |
| 52 Week Low | $1.57 | $2.77 |
| 52 Week High | $6.04 | $7.18 |
Technical Indicators
Market Signals| Indicator | PGEN | RXRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.35 | 44.48 |
| Support Level | $3.96 | $2.87 |
| Resistance Level | $6.04 | $4.03 |
| Average True Range (ATR) | 0.28 | 0.18 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 82.95 | 24.52 |
Price Performance
Historical ComparisonAbout PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.